Pharma Companies Compete to Make Biotech Asthma Drugs

Rival firms are racing to develop injectable biotech asthma drugs for patients with severe disease who don't respond well to traditional inhalers, in pursuit of a new market worth a possible $7.5 billion.

Despite treatment advances in recent decades, asthma is still not well controlled in up to 20 percent of patients on standard therapy, which consists of inhaled steroids and long-acting beta agonists that are designed to open the airways. Read the full story